IA
AVEO

Inspire Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Inspire Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-80
Closed – – 823
2020
Q4 		$0 Buy
+80
New +$458 ﹤0.01% 832

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Inspire Advisors's AVEO Position: Q1 2021 in Review

Inspire Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2021, closing a stake of 80 shares.

Inspire Advisors first reported a position in AVEO in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 76 funds tracked by Wall St. Rank hold AVEO as of Q1 2021.

  • Inspire Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Inspire Advisors sold 80 AVEO Pharmaceuticals, Inc. shares in Q1 2021.
  • Inspire Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Inspire Advisors's AVEO Pharmaceuticals, Inc. position peaked at $0 in Q4 2020.
  • 76 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.